uniQure NV Company Profile (NASDAQ:QURE)

Analyst Ratings

Consensus Ratings for uniQure NV (NASDAQ:QURE) (?)
Ratings Breakdown: 10 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $32.11 (347.85% upside)

Analysts' Ratings History for uniQure NV (NASDAQ:QURE)
Show:
DateFirmActionRatingPrice TargetActions
7/18/2016Chardan CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016WallachBeth CapitalLower Price TargetBuy$60.00 -> $35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/12/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2016HC WainwrightReiterated RatingBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/8/2016Janney Montgomery ScottReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/8/2016Roth CapitalReiterated RatingBuy$37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2015BMO Capital MarketsReiterated RatingOutperform -> PositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for uniQure NV (NASDAQ:QURE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/25/2016        
5/31/2016Q1($0.82)($0.93)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/4/2016Q415($0.60)($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/30/2015Q315($0.64)($1.14)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/27/2015Q215($0.56)($0.98)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
6/11/2015Q1($0.82)($0.69)$9.50 million$1.17 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/6/2015($0.62)($0.77)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/1/2014($0.53)($0.61)$2.00 million$1.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/2/2014Q214($0.55)($1.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
6/6/2014($0.45)($0.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for uniQure NV (NASDAQ:QURE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.94)($0.63)($0.75)
Q2 20163($0.98)($0.74)($0.85)
Q3 20163($1.00)($0.77)($0.87)
Q4 20163($1.03)($0.80)($0.90)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for uniQure NV (NASDAQ:QURE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for uniQure NV (NASDAQ:QURE)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for uniQure NV (NASDAQ:QURE)
DateHeadline
07/21/16 06:23 PMuniQure N.V. (NASDAQ:QURE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 06:54 PMEPS Roundup: BJ's Restaurants, Inc. (NASDAQ:BJRI), uniQure N.V. (NASDAQ:QURE), Six Flags Entertainment ... - Engelwood Daily
07/20/16 08:52 AMEquity Roundup: Stock Performance Focus on uniQure N.V. (NASDAQ:QURE) - Press Telegraph
07/19/16 06:10 PMAs Gene Therapies Disrupt Big Pharma, Here's How to Get Your Piece of the Action
07/19/16 07:00 AMHow Many Uniqure NV (NASDAQ:QURE)'s Analysts Are Bearish? - Consumer Eagle
07/19/16 07:00 AMEarnings Focus and Crowd Sourced Sentiment Review for uniQure N.V. (NASDAQ:QURE) - TGP
07/17/16 05:27 PMUniqure BV (NASDAQ:QURE) Broker Price Targets For The Coming Week - Fiscal Standard
07/17/16 05:27 PMUniqure NV Ord (NASDAQ:QURE) Shorted Shares Increased 4.23% After Market Selling - Consumer Eagle
07/16/16 05:31 PMUniqure NV Just Recorded A Sigfniciant Decline - Consumer Eagle
07/14/16 09:40 AMWill uniQure N.V. (NASDAQ:QURE) Surprise Analysts? - Investor Newswire
07/14/16 09:40 AMAnalyst Target and Average Rating Watch: uniQure N.V. (NASDAQ:QURE) - Press Telegraph
07/11/16 12:54 PMuniQure Announces Oral Presentation of Updated Results for AMT-060 at the World Federation of Hemophilia (WFH) 2016 World Congress - [GlobeNewswire] - AMSTERDAM, The Netherlands -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that updated data from its ongoing Phase I/II clinical study of AMT-060 in hemophilia B patients ...
07/09/16 05:25 PMBRIEF-UniQure appoints Jonathan Garen as chief business officer - Reuters
07/08/16 08:56 AMUniqure NV Ord (NASDAQ:QURE) Sellers Increased By 4.23% Their Shorts - Press Telegraph
07/08/16 08:56 AMuniQure NV Stock Momentum at Critical Inflection Point - CML News
07/07/16 08:51 AMCompany Stock Focus for uniQure N.V. (NASDAQ:QURE): Which Way Will Shares Head? - Press Telegraph
07/07/16 08:51 AMCompany Update (NASDAQ:QURE): Uniqure NV Appoints Jonathan Garen as Chief Business Officer - Smarter Analyst
07/07/16 06:31 AMuniQure Appoints Jonathan Garen as Chief Business Officer - [at noodls] - Amsterdam, the Netherlands, July 7, 2016 - uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the appointment of Jonathan Garen as Chief Business Officer. Mr. Garen has more than ...
07/04/16 05:13 PMAre Analysts Bearish Uniqure NV (NASDAQ:QURE) After Last Week? - Engelwood Daily
07/04/16 05:13 PMIt Seems Uniqure NV Will Go Up. Have Another Big Increase - Press Telegraph
06/30/16 08:51 AMProtein Sciences Announces Exclusive License to uniQure of Cell Line and Technology for Production of Human Gene ... - PR Newswire (press release)
06/30/16 08:51 AMCovering the Bases on uniQure N.V. (NASDAQ:QURE): Where is the Stock Going? - Press Telegraph
06/28/16 05:56 PMDiscover the amyotrophic lateral sclerosis pipeline landscape and therapeutics under development market review 2016
06/28/16 10:52 AMProtein Sciences Announces Exclusive License to uniQure of Cell Line and Technology for Production of Human Gene Therapies
06/27/16 05:59 PMuniQure Appoints Maria E. Cantor as Senior Vice President, Investor Relations & Communications - GlobeNewswire (press release)
06/27/16 05:59 PMuniQure Appoints Maria E. Cantor as Senior Vice President, Investor Relations Communications - EconoTimes
06/24/16 08:39 AMBiotechnology Decliners: uniQure N.V. (NASDAQ:QURE), ImmunoGen, Inc. (NASDAQ:IMGN), Alexion Pharmaceuticals ... - KC Register
06/24/16 08:39 AMuniQure N.V. (NASDAQ:QURE) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 08:39 AMCould Uniqure NV See a Reversal After This Very Weak Session? - Press Telegraph
06/24/16 08:39 AMUniqure NV Ord (NASDAQ:QURE) Sellers Covered 4.69% of Their Shorts - Press Telegraph
06/21/16 10:23 AMTrader's Watch List: uniQure N.V. (NASDAQ:QURE), Bon-Ton Stores Inc. (NASDAQ:BONT), Rite Aid (NYSE:RAD ... - KC Register
06/17/16 05:49 PMNew Data Spark Hemophilia B Gene Therapy Battle - Seeking Alpha
06/15/16 05:57 PMUniqure NV 271.2% Potential Upside Now Implied by WallachBeth - DirectorsTalk Interviews
06/12/16 10:55 PM11:55 pm uniQure reports Phase I/II clinical data demonstrating 6 months of sustained increases in Factor IX activity -
06/11/16 08:56 AMuniQure NV: uniQure Presents Clinical Data from Ongoing Phase I/II Study in Hemophilia B Demonstrating 6 Months of ... - The Wall Street Transcript
06/11/16 04:49 AMuniQure Presents Clinical Data from Ongoing Phase I/II Study in Hemophilia B Demonstrating 6 Months of Sustained Increases in Factor IX Activity - [at noodls] - --Data from Low-Dose Cohort Presented at the 21st Congress of the European Hematology Association Show Durable and Therapeutically Relevant Factor IX (FIX) Expression-- --Median FIX Activity for All Five ...
06/10/16 09:03 AMTrend Of Rating Given To uniQure N.V. (NASDAQ:QURE) - Investor Newswire
06/08/16 06:32 PMUNIQURE NV (NASDAQ:QURE) Financial Condition Compared to S&P 500 - CML News
06/08/16 09:04 AMAMN Healthcare Services Inc. (NYSE:AHS) increased 3.06%: uniQure N.V. (NASDAQ:QURE), Rent-A-Center, Inc ... - KC Register
06/07/16 10:12 AMuniQure NV :QURE-US: Earnings Analysis: Q1, 2016 By the Numbers : June 7, 2016 -
06/07/16 08:48 AMRevenue Update on Uniqure NV(NASDAQ:QURE) - Trade Calls
06/05/16 08:43 AMAre Analysts Bearish Uniqure NV (NASDAQ:QURE) After Last Week? - HNN
06/04/16 06:04 PMUniqure NV (QURE) Stock Rating Reaffirmed by Oppenheimer - Let Me Know About This
06/04/16 08:58 AMUniqure NV (QURE) Earns “Buy” Rating from Jefferies Group - Let Me Know About This
06/03/16 06:37 PMEquities Analysts Set Expectations for Uniqure NV's Q2 2016 Earnings (QURE) - Let Me Know About This
06/02/16 06:29 PMuniQure N.V. (NASDAQ:QURE) Stock Update & Estimates - Stock Tick Tock - uniQure N.V. (NASDAQ:QURE) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting uniQure N.V. (NASDAQ:QURE) to post earnings of $-0.83 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued around ...and more »
06/02/16 09:02 AMUniqure NV (QURE) Receives “Buy” Rating from Cowen and Company - Let Me Know About This - Uniqure NV (QURE) Receives “Buy” Rating from Cowen and CompanyLet Me Know About ThisUniqure NV logo Uniqure NV (NASDAQ:QURE)'s stock had its “buy” rating reissued by analysts at Cowen and Company in a report issued on Thursday. QURE has been the subject of a number of other reports. Chardan Capital reissued a “buy” rating and ...Cowen and Company Reiterates Buy Rating for Uniqure NV (QURE)The Cerbat GemUniqure BV (NASDAQ:QURE) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsuniQure NV (NASDAQ:QURE) Stock Update & EstimatesStock Tick Tockall 4 news articles »
06/01/16 08:58 AMHot Stock to Track: Uniqure NV (NASDAQ:QURE) - The Point Review - Hot Stock to Track: Uniqure NV (NASDAQ:QURE)The Point ReviewUniqure NV (NASDAQ:QURE) has a market cap of $329.40 million and the number of outstanding shares have been calculated to be 24.33 million shares. One more important factor to consider when evaluating a stock's current and future value are the 52 ...Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), uniQure N.V. (NASDAQ: QURE), Amarin ...Analyst Ratingsall 2 news articles »
05/31/16 06:22 PMUniqure NV (QURE) Releases Earnings Results, Misses Estimates By $0.10 EPS - Let Me Know About This - Uniqure NV (QURE) Releases Earnings Results, Misses Estimates By $0.10 EPSLet Me Know About ThisUniqure NV logo Uniqure NV (NASDAQ:QURE) issued its earnings results on Tuesday. The company reported ($0.93) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.82) by $0.10. Shares of Uniqure NV ...
05/31/16 06:22 PMCompany Update (NASDAQ:QURE): Uniqure NV Announces Results for First Quarter 2016 - Smarter Analyst - Company Update (NASDAQ:QURE): Uniqure NV Announces Results for First Quarter 2016Smarter AnalystUniqure NV (NASDAQ:QURE), a leader in human gene therapy, announced financial results for the first quarter ending March 31, 2016, and provided a corporate update. “We are very pleased with our progress so far in 2016 as we continue to advance our ...uniQure Q1 Loss Misses Street Mark, Beats on Revenues (NASDAQ:QURE)Sonoran Weekly ReviewBroker Outlook For The Week Ahead: Uniqure BV (NASDAQ:QURE)Share Trading Newsall 3 news articles »

Social

About uniQure NV

uniQure NV logoUniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. The Company's first product is Glybera, for the treatment of lipoprotein lipase deficiency (LPLD). In the clinical pipeline, it has gene treatments for hemophilia, porphyria, Parkinson, Sanfilippo B syndrome and hearing loss. Additionally, it is engaged in the development of therapies based on adeno-associated virus (AAV) through multiple collaborations. The Company uses modular technology platform, including a cost effective manufacturing process. In August 2014, Uniqure NV acquired InoCard GmbH, an early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: QURE
  • CUSIP:
Key Metrics:
  • Previous Close: $7.17
  • 50 Day Moving Average: $8.75
  • 200 Day Moving Average: $12.69
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $175.72M
  • Beta: 0.21
  • Current Year EPS Consensus Estimate: $-3.44 EPS
  • Next Year EPS Consensus Estimate: $-2.96 EPS
Additional Links:
uniQure NV (NASDAQ:QURE) Chart for Monday, July, 25, 2016